Recruiting

Rowing Following Breast Cancer Chemotherapy

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

ClinicalTrials.gov IDNCT05848141

PhaseNA

Enrollment72

SponsorUniversity of Florida

Age40 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer Survivors

About this study

Interventions

Behavioral: Exercise training — This is a single site center-based supervised exercise intervention.

Primary outcomes

Change in brachial FMD (Baseline, Following 12 weeks of supervised exercise training)
Change in global longitudinal strain (Baseline, Following 12 weeks of supervised exercise training)
% completed vs. planned exercise frequency (Throughout the 12 weeks of supervised exercise training)
% completed vs. planned exercise duration (Throughout the 12 weeks of supervised exercise training)
% completed vs. planned exercise intensity (Throughout the 12 weeks of supervised exercise training)
Number of participants who experience adverse event as defined by most recent CTCAE (Throughout the 12 weeks of supervised exercise training)

Eligibility information

Inclusion Criteria: * diagnosis of primary invasive non-metastatic breast cancer, stages I-III * female based on biological sex * 40 to 80 years of age * completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation * absence of contraindications to exercise or study participation * study clinician approval Exclusion Criteria: * do not meet inclusion criteria * receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation * lymphedema stage ≥ 2 prior to study enrolment * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss) * consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months

Study locations

Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida 32611 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.